Tricyclic Covalent Inhibitors Selectively Target Jak3 through an Active Site Thiol
|
journal
|
February 2015 |
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|
journal
|
August 2013 |
Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance
|
journal
|
December 2013 |
Adverse event potentially due to an interaction between ibrutinib and verapamil: a case report
|
journal
|
January 2016 |
Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling
|
journal
|
December 2014 |
Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma
|
journal
|
April 2015 |
Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia
|
journal
|
April 2015 |
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
|
journal
|
February 2005 |
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia
|
journal
|
April 2015 |
Bruton's TK inhibitors: structural insights and evolution of clinical candidates
|
journal
|
April 2014 |
Postibrutinib outcomes in patients with mantle cell lymphoma
|
journal
|
March 2016 |
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
|
journal
|
August 2002 |
BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity
|
journal
|
November 2013 |
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
|
journal
|
January 2016 |
A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors
|
journal
|
July 2014 |
Discovery of a Selective Irreversible BMX Inhibitor for Prostate Cancer
|
journal
|
April 2013 |
Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation
|
journal
|
July 2015 |
Antiarthritis Effect of a Novel Bruton's Tyrosine Kinase (BTK) Inhibitor in Rat Collagen-Induced Arthritis and Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling: Relationships between Inhibition of BTK Phosphorylation and Efficacy
|
journal
|
April 2011 |
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
|
journal
|
January 2013 |
Inhibition of Btk with CC-292 Provides Early Pharmacodynamic Assessment of Activity in Mice and Humans
|
journal
|
May 2013 |
A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies
|
journal
|
January 2016 |
The clinical safety of ibrutinib in chronic lymphocytic leukemia
|
journal
|
August 2015 |
Prolonged and tunable residence time using reversible covalent kinase inhibitors
|
journal
|
May 2015 |
The resurgence of covalent drugs
|
journal
|
April 2011 |
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
|
journal
|
June 2014 |
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
|
journal
|
July 2004 |
Epidermal Growth Factor Receptor Inhibitor–Associated Cutaneous Toxicities: An Evolving Paradigm in Clinical Management
|
journal
|
May 2007 |
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
|
journal
|
July 2010 |
Functional characterization of BTKC481S mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors
|
journal
|
September 2014 |
Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia
|
journal
|
June 2016 |
Potent and selective Bruton’s tyrosine kinase inhibitors: Discovery of GDC-0834
|
journal
|
March 2015 |
Selective Inhibition of BTK Prevents Murine Lupus and Antibody-Mediated Glomerulonephritis
|
journal
|
September 2013 |
Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases: Crystal Structures of Human BTK Kinase Domain
|
journal
|
January 2010 |
RN486, a Selective Bruton's Tyrosine Kinase Inhibitor, Abrogates Immune Hypersensitivity Responses and Arthritis in Rodents
|
journal
|
January 2012 |
Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase
|
journal
|
January 2007 |
Ibrutinib Resistance in Chronic Lymphocytic Leukemia
|
journal
|
June 2014 |
Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes
|
journal
|
June 2015 |
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|
journal
|
July 2013 |
Discovery of highly potent and selective Bruton’s tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stability
|
journal
|
January 2016 |
Bruton’s Tyrosine Kinase Inhibitors: Approaches to Potent and Selective Inhibition, Preclinical and Clinical Evaluation for Inflammatory Diseases and B Cell Malignancies
|
journal
|
March 2012 |
Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers
|
journal
|
January 2009 |
Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer
|
journal
|
December 2012 |
Specific Btk inhibition suppresses B cell– and myeloid cell–mediated arthritis
|
journal
|
November 2010 |
Use of tumor genomic profiling to reveal mechanisms of resistance to the BTK inhibitor ibrutinib in chronic lymphocytic leukemia (CLL).
|
journal
|
May 2013 |